Heart Failure With Preserved Ejection Fraction

PHILADELPHIA — Heart failure with preserved ejection fraction may be misdiagnosed in patients with COPD due to symptoms/signs being misinterpreted as COPD, according to a presentation at the 2024 GOLD COPD International Conference.

Carelog announced its ECG-based algorithm received FDA breakthrough device designation for detection of diastolic dysfunction, an early predictor of HF with preserved ejection fraction.

A novel controlled metabolic accelerator was associated with weight loss in patients with obesity-related heart failure with preserved ejection fraction, according to phase 2a study results.

Treatment of obesity-related HF with preserved ejection fraction with semaglutide 2.4 mg improved body weight, physical function and HF symptoms regardless of the extent of patient frailty, a speaker reported.

In patients with HF and ejection fraction 40% or greater, the absolute risk reduction for total worsening HF events and CV death with finerenone vs. placebo was greatest in those with recent worsening HF, new data from FINEARTS-HF show.

In a phase 2a trial of patients with obesity-related HF with preserved ejection fraction, a novel controlled metabolic accelerator was associated with weight loss at 3 months compared with placebo.

Semaglutide cut the risk for worsening heart failure and CV death for adults with HF with preserved ejection fraction, according to data presented at the European Society of Cardiology Congress and simultaneously published in The Lancet.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.

GLP-1 receptor agonist use on top of SGLT2 inhibition in patients with HF with preserved ejection fraction, type 2 diabetes and obesity was associated with reduced risk for adverse events vs. SGLT2 inhibition alone, researchers reported.

Bayer announced positive top-line results for the FINEARTS-HF trial of finerenone, in which the drug reduced risk for cardiovascular death and heart failure events in patients with HF with preserved or mildly reduced ejection fraction.